Trulieve Reports Q2 2026 Earnings; Revenue and Margin Trends in Focus

Revenue and Store Count

Trulieve disclosed Q2 revenue figures and updated its dispensary footprint, with Florida accounting for the majority of retail locations. The company operates over 180 dispensaries across the U.S., concentrated heavily in Florida, where it holds approximately 50% market share in the state's medical cannabis program. Management outlined same-store sales trends. Pricing pressure in mature markets got airtime, too.

The MSO has maintained a steady pace of new store openings in 2026, targeting underserved Florida counties and select markets in Pennsylvania, Arizona, and West Virginia.

Margin Performance and Cost Management

Gross margin and adjusted EBITDA remained central topics, with management addressing cultivation efficiency and SG&A leverage. Trulieve has historically posted gross margins in the 60-65% range, supported by vertical integration and in-house cultivation. The Q2 call included commentary on input-cost inflation, labor expenses, and the company's ongoing cost-reduction initiatives.

Trulieve's ability to maintain margin discipline in a deflationary pricing environment will be a key signal for investors watching Florida's transition to adult-use sales.

Florida Adult-Use Ballot Measure

November's ballot initiative to legalize adult-use cannabis in Florida looms as the single largest variable in Trulieve's near-term outlook. Trulieve has committed over $50 million to the Smart & Safe Florida campaign backing Amendment 3, which requires 60% voter approval to pass. Management discussed readiness plans, inventory positioning, and capital allocation in the event of passage.

If approved, Florida's adult-use market could generate $4-6 billion in annual sales within three years, according to industry forecasts. Trulieve's existing infrastructure positions it to capture early share.

Cash Flow and Capital Allocation

Free cash flow generation and debt-service priorities were addressed, with Trulieve carrying approximately $650 million in senior notes due 2026-2028. Debt reduction has taken precedence over M&A in recent quarters. The company's been using operating cash flow to pay down term-loan balances and extend maturities. Management provided updated guidance on capital expenditures and liquidity runway.

• Operating cash flow trends and working-capital efficiency
• Debt refinancing timeline and interest-rate exposure
• Share-buyback authorization status (currently paused)

Guidance and Outlook

Trulieve reaffirmed or updated full-year 2026 revenue and EBITDA guidance, contingent on Florida ballot outcomes and federal scheduling developments. The second half is volatile: DEA rescheduling remains in administrative limbo, SAFE Banking has stalled again in Congress, and Florida voters will decide the adult-use question in 90 days.

Analysts will be watching same-store sales velocity, gross-margin stability, and free-cash-flow conversion as the company works through an uncertain regulatory and competitive environment. For full background on this story, see the CannIntel topic hub on Trulieve Q2 2026 Earnings.

Next earnings call: November 2026, post-election.